The Ethiopian government is offering tax and loan incentives to encourage local pharmaceutical production in a bid to reduce drug costs, boost jobs, improve economic growth and enhance foreign exchange inflow.
Ethiopia has always relied on pharmaceutical imports or international manufacturers with a footprint in the country to meet a growing demand for medicine.
The country has an increasing requirement of antibiotics, as well as anti-infective drugs, given the high incidences of communicable diseases in the country and an ever-growing population. This in turn is fuelling the need for chronic care medication. As a result, several initiatives are to be rolled out to improve the quality of healthcare in the country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze